 |
인쇄하기
취소
|
Kwangdong to introduce new nucleoside analog RP101
Kwangdong Pharm says it has entered into an exclusive license with Germany based with respect to its lead drug candidate, RP101, for the treatment of pancreatic cancer.
The company will launch in RP101 in Korea in 2012 after completion of clinical trials and registration procedures.
RESprotect GmbH is a biotechnology firm located in Dresden specializing in the prevention of chemoresistanc...
The company will launch in RP101 in Korea in 2012 after completion of clinical trials and registration procedures.
RESprotect GmbH is a biotechnology firm located in Dresden specializing in the prevention of chemoresistanc...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.